



NAMS NEWS

New HT Report Available at NAMS Meeting

At the upcoming NAMS Annual Meeting (September 17-20 in Miami Beach), attendees will have an opportunity to learn the latest about "Prevention of Disease Through Menopause and Beyond," as well as how to treat menopause symptoms. A meeting highlight will be the presentation of the 2003 NAMS HT Advisory Panel Report, which will provide the Society's analysis of the most current scientific literature relating to hormone therapy (HT) for menopause-related conditions. Chaired by NAMS Executive Director and this publication's Editor, Wulf H. Utian, MD, PhD,

Plan Ahead

15th NAMS Meeting

October 6-9, 2004
Washington, DC

16th NAMS Meeting

September 28-October 1, 2005
San Diego, CA

the Panel is composed of leaders in the field. After its unveiling at the Annual Meeting, the report will be distributed widely and published in the Society's media outlets (ie, www.menopause.org, *Menopause*, and *Menopause Management*). It undoubtedly will be as eagerly awaited as was last year's report.

The 2002 NAMS Report (published in the January/February 2003 issue of *Menopause Management*) was presented by invitation to the National Institutes of Health. This report also influenced the FDA's recent revisions to labeling for hormone therapy products.

Updated Menopause Guidebook Available

Since the WHI findings were published and the FDA modified labeling for hormones, NAMS has worked very hard to publish an updated *Menopause Guidebook*," said Kayt K. Havens, MD, Chair of the NAMS Consumer Education Committee. "I am pleased to announce that the new con-

sumer resource is now available. The content of the 60-page guidebook is even more comprehensive, the design has been refreshed to invite readership, and, importantly, pricing remains affordable for all practices [as low as \$1 each]."

A preview copy of the guidebook currently is posted on the NAMS Web site; and a Spanish translation will be added soon. At the same time, the National Braille Press has a braille edition available free of charge.

The development of the *Menopause Guidebook* was supported by an unrestricted educational grant from Berlex Laboratories. The grantor had no control over the contents.

Progestogen Position Statement Published

The March/April 2003 issue of *Menopause* contains the newest NAMS Position Statement—one addressing the role of progestogen in estrogen-progestogen therapy for postmenopausal women. The Society appreciates the work of the Editorial Board, chaired by Rogerio A. Lobo, MD. It was edited and subsequently approved by the NAMS Board of Trustees in November 2002. The Society hopes that the Position Statement is helpful to practicing clinicians and researchers.

The document is also posted on the NAMS Web site, and, it appears in two parts in *Menopause Management* (Part 1 in the May/June 2003 issue; Part 2 in this issue).

ADVERTISERS' INDEX

Amerifit Nutrition, Inc.

Estroven 15

Aventis Pharmaceuticals

Actonel IBC, OBC

Duramed Pharmaceuticals, Inc.,

a subsidiary of
Barr Laboratories, Inc.

Cenestin IFC, 1, 2

Monarch Pharmaceuticals

Prefest 5, 6

North American Menopause Society, The

..... 9

Solvay Pharmaceuticals

Estratest 24a, 24b

Warner Chilcott, Inc.

Femring 8a, 8b

Watson Pharma, Inc.

Oxytrol 16a - 16d

Important NAMS Dates

2003 Annual Meeting

September 17-20
(NEW: Meeting opens Wednesday,
September 17, at 5:30 p.m.)

2003 Abstracts Submission

Late-Breaking Deadline: July 15
(paper submission only)

Menopause Basics Course

September 17 (8 a.m.-Noon)

Next Competency Exam

September 17 (2:30 - 4:30 p.m.)
Early-Bird Deadline: July 9
Final Deadline: August 6

NAMS Central Office:

The North American Menopause Society
5900 Landerbrook Drive, Suite 195
Mayfield Heights, OH 44124

Mailing Address:

Post Office Box 94527
Cleveland, OH 44101-4527

Phone: 440/442-7550

Fax: 440/442-2660

E-mail Address: info@menopause.org

Web Site: <http://www.menopause.org>